Related Articles
Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB
SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer
Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer
Investigating the discernible and distinct effects of platinum‑based chemotherapy regimens for metastatic triple‑negative breast cancer on time to progression
Platinum‑based chemotherapy in triple‑negative breast cancer: A meta‑analysis